TGTX: Multiplikator Forward P/S TG Therapeutics Corp

Simbol lan logo merek TG Pharma (TGTX)

TG Therapeutics, Inc. (TGTX) relies on the expansion of Briumvi and the growth of insurance coverage. The company is implementing innovative biological therapies to combat oncohematology and sclerosis. The projected price-to-sales valuation allows for the tracking of forward multiple compression, where 2.60 represents the current level of the metric. The successful launch of products is driven by the high competence of the management team led by Michael Weiss.

TGTX (TG Therapeutics Inc) riwayat Rega forward marang dodolan saka 04.07.2022 nganti 17.11.2026

Rincian metrik komprehensif lan analitis TG Therapeutics, Inc. (TGTX)

- rega saham lan target rega konsensus:
Analisis wiwitan perusahaan:TGTX (TG Therapeutics Corp)
Sampel barang TG Pharma

TG Therapeutics, Inc. (TGTX) maintains resilience to market shocks through a production outsourcing strategy, which minimizes capital expenditures and capacity shortage risks. The current value of 2.60 in the forward P/S metric reflects the ratio of the company's market capitalization to expected revenue, allowing investors to assess the extent of future growth priced in and the risk of overpaying for business scalability.